Table 1. Characteristics of Included Trials (Non–Vitamin K Antagonist Oral Anticoagulants vs Aspirin).

Study Acronym	Qualifying Condition	Mean Age, y	Total Patients, No.	Female, No./Total No. (%)	Active Group, No.	Active Treatment	Control Group	Control Treatment	Follow-Up, y	Intracranial Hemorrhage
										Events in Active Arm, No.	Events in Control Arm, No.
Apixabana
AVERROES, 201423	Atrial fibrillation unsuitable for vitamin K antagonist	70	5599	2322 (41.5)	2808	Apixaban, 5 mg twice daily	2791	Aspirin, 81 to 324 mg once daily	1.1	11	13
Rivaroxabanb
EINSTEIN CHOICE, 201722	Venous thromboembolism	58.5	3365	1500 (44.6)	2234	Rivaroxaban, 20 mg once daily (1107 participants) or 10 mg once daily (1127 participants)	1131	Aspirin, 100 mg once daily	1	3 (20 mg); 1 (10 mg)	2
COMPASS, 201720	Stable cardiovascular disease	68.2	18 243	3961 (21.7)	9117	Rivaroxaban, 5 mg twice daily	9126	Aspirin, 100 mg once daily	1.9	43	24
COMPASS, 201721	Stable peripheral or carotid artery disease	67.8	4978	1391 (27.9)	2474	Rivaroxaban, 5 mg twice daily	2504	Aspirin, 100 mg once daily	1.8	6	9
NAVIGATE ESUS, 20186	Embolic strokes of undetermined source	67	7213	2777 (38.5)	3609	Rivaroxaban, 15 mg once daily	3604	Aspirin, 100 mg once daily	0.92	20	5

Abbreviations: AVERROES, Apixaban vs Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; COMPASS, Cardiovascular Outcomes for People Using Anticoagulation Strategies; EINSTEIN CHOICE, Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism; NAVIGATE ESUS, Rivaroxaban vs Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source.

^aThis study used apixaban in the active study arm.

^bThese studies used rivaroxaban in the active study arm.